Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures
Completed
Primary Children's Hospital
Phase 2
2006-06-01
The investigators will conduct a randomized controlled trial comparing the use of nasal
midazolam, using a Mucosal Atomization Devise, to rectal diazepam for the treatment of acute
seizure activity in children under the age of 18 years with epilepsy in the community
setting. The primary hypothesis is that nasal midazolam will be more effective and have
shorter seizure time compared to rectal diazepam in the community. The secondary hypotheses
are that patients treated with nasal midazolam will have fewer respiratory complications,
emergency department visits, and admissions.
Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures
Completed
University of Utah
Phase 2
2006-06-01
The investigators will conduct a randomized controlled trial comparing the use of nasal
midazolam, using a Mucosal Atomization Devise, to rectal diazepam for the treatment of acute
seizure activity in children under the age of 18 years with epilepsy in the community
setting. The primary hypothesis is that nasal midazolam will be more effective and have
shorter seizure time compared to rectal diazepam in the community. The secondary hypotheses
are that patients treated with nasal midazolam will have fewer respiratory complications,
emergency department visits, and admissions.
A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers
Completed
Neurelis, Inc.
Phase 1
2011-02-01
The purpose of this clinical research study is to assess the bioavailability and
pharmacokinetics of two formulations of diazepam after intranasal (nasal spray) and
injectable diazepam after intravenous (I.V.) administration
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
